Patricia Lorenzini

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

9h-index1.3kcitations22works32.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(17), Colorectal Cancer Treatments and Studies(9), Gastric Cancer Management and Outcomes(7), Lung Cancer Diagnosis and Treatment(4), Lung Cancer Research Studies(3)

Publications22 total

Amivantamab Plus Lazertinib in Atypical <i>EGFR</i> -Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2
Journal of Clinical Oncology·2025Open Access
Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC
Lung Cancer·2025
OrigAMI-3: A randomized, phase 3 study of amivantamab plus FOLFIRI vs cetuximab or bevacizumab plus FOLFIRI in participants with recurrent, unresectable, or metastatic <i>RAS/BRAF</i> wild-type colorectal cancer.
Journal of Clinical Oncology·2025· 1 cited
OrigAMI-2: A randomized, phase 3 study of amivantamab vs cetuximab, both in combination with FOLFOX or FOLFIRI, as first-line treatment in left-sided <i>RAS</i> / <i>BRAF</i> wild-type metastatic colorectal cancer.
Journal of Clinical Oncology·2025
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study
Journal of Thoracic Oncology·2025· 12 citedOpen Access
Amivantamab with or without chemotherapy in right-sided metastatic colorectal cancer: Updated results from OrigAMI-1, an open-label, phase 1b/2 study.
Journal of Clinical Oncology·2025· 2 cited
Patient-Reported Outcomes and Time to Symptomatic Progression from Papillon: Amivantamab Plus Chemotherapy vs Chemotherapy as First-Line Treatment of Egfr Exon 20 Insertion-Mutated Advanced Nsclc
SSRN Electronic Journal·2025Open Access
MA12.06 PAPILLON: TP53 Co-mutations, Sites of Insertion, and ctDNA Clearance Among Patients with EGFR Ex20ins-Mutated Advanced NSCLC
Journal of Thoracic Oncology·2024· 3 citedOpen Access
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
New England Journal of Medicine·2024· 310 citedOpen Access
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study
Journal of Clinical Oncology·2024· 95 citedOpen Access
Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.
Journal of Clinical Oncology·2024· 1 cited
Abstract CT054: Amivantamab in wild-type advanced non-small cell lung cancer after disease progression on checkpoint inhibition and chemotherapy: Results from the phase 1b CHRYSALIS study
Cancer Research·2024· 1 cited
7P Patient-relevant endpoints from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated (Ex20ins) advanced NSCLC
ESMO Open·2024· 2 citedOpen Access
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial
Nature Medicine·2023· 97 citedOpen Access
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study
Lung Cancer·2023· 24 citedOpen Access
MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study
Annals of Oncology·2022· 1 citedOpen Access
1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab
Annals of Oncology·2021· 2 cited
Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study
Journal of Clinical Oncology·2021· 599 citedOpen Access
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414)
JTO Clinical and Research Reports·2020· 16 citedOpen Access
1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC
Annals of Oncology·2020· 40 cited
page 1 of 2Next →

Frequent Co-authors

Roland E. Knoblauch(15), Mahadi Baig(13), Joshua K. Sabari(12), Alexander I. Spira(12), Byoung Chul Cho(12), Meena Thayu(10), Rachel E. Sanborn(9), Joshua Bauml(9), Eric B. Haura(8), John Xie(8), Joshua C. Curtin(8), Keunchil Park(7), Catherine A. Shu(6), Nicolas Girard(6), Ji‐Youn Han(6), Amy Roshak(6), Natasha B. Leighl(5), Ki Hyeong Lee(5), James Chih‐Hsin Yang(5), Dawn Millington(5)